Criteria Fulfill
Item
patients are eligible to be included in the study only if they meet all of the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Chronic Lymphocytic Leukemia | CD19 Expressing Cell Count Flow Cytometry | CD5 Expressing Cell Measurement Flow Cytometry | CD23 Antigen Flow Cytometry
Item
1. patients with b-cell cll as diagnosed by expression of cd19, cd5, and cd23 by flow cytometry.
boolean
C0023434 (UMLS CUI [1])
C3540683 (UMLS CUI [2,1])
C0016263 (UMLS CUI [2,2])
C3538992 (UMLS CUI [3,1])
C0016263 (UMLS CUI [3,2])
C0123242 (UMLS CUI [4,1])
C0016263 (UMLS CUI [4,2])
Disease Rai Staging System | Indication Therapeutic procedure
Item
2. rai stage iii or iv disease or earlier stage disease with indications for therapy per nci working group criteria (cheson et al. 1996)
boolean
C0012634 (UMLS CUI [1,1])
C1514715 (UMLS CUI [1,2])
C3146298 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
Absolute lymphocyte count | Determination of percentage differential white blood cells
Item
3. absolute lymphocyte count > or = to 5,000/microliter, with a lymphocyte wbc differential of > or = to 70%.
boolean
C3544087 (UMLS CUI [1])
C0579194 (UMLS CUI [2])
Platelet Count measurement
Item
4. platelet count >20,000/microliter.
boolean
C0032181 (UMLS CUI [1])
Organ function
Item
5. adequate organ function, including the following:
boolean
C0678852 (UMLS CUI [1])
Liver function | Serum total bilirubin measurement | Alkaline phosphatase measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
hepatic: bilirubin < or = to 1.5 times the upper limit of normal (x uln); alkaline phosphatase (alp), aspartate transaminase (ast), and alanine transaminase (alt) < or = to 2.5 x uln
boolean
C0232741 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201850 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
Renal function | Creatinine measurement, serum
Item
renal: serum creatinine < or = to 1.5 x uln.
boolean
C0232804 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Criteria Fulfill
Item
patients will be excluded from the study if they meet any of the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Lacking Able to swallow Tablets
Item
1. are unable to swallow tablets.
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,3])
Carbamazepine Discontinue Unable | Phenobarbital Discontinue Unable | Phenytoin Discontinue Unable
Item
2. are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.
boolean
C0006949 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C0031412 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C1299582 (UMLS CUI [2,3])
C0031507 (UMLS CUI [3,1])
C1444662 (UMLS CUI [3,2])
C1299582 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
3. are pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
CNS metastases | Exception Local Therapy Completed | Exception Adrenal Cortex Hormones Discontinued
Item
4. have central nervous system (cns) metastases (unless the patient has completed successful local therapy for cns metastases and has been off of corticosteroids for at least 4 weeks before starting study therapy).
boolean
C0686377 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1517925 (UMLS CUI [2,2])
C0205197 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0001617 (UMLS CUI [3,2])
C1444662 (UMLS CUI [3,3])
Comorbidity Serious Systemic | Bacterial Infection | Mycoses | Virus Disease | Comorbidity compromises Protocol Compliance
Item
5. have a serious concomitant systemic disorder (including active bacterial, fungal, or viral infection) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol.
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205373 (UMLS CUI [1,3])
C0004623 (UMLS CUI [2])
C0026946 (UMLS CUI [3])
C0042769 (UMLS CUI [4])
C0009488 (UMLS CUI [5,1])
C2945640 (UMLS CUI [5,2])
C0525058 (UMLS CUI [5,3])